Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 7/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15726868 | 0.74 | DYRK1A (0.39) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL23530790 | 0.74 | ALDH1A1 (0.44) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL3118472 | 0.74 | DYRK1A (0.39) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL3117779 | 0.74 | DYRK1A (0.39) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL5337466 | 0.74 | DYRK1A (0.39) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL10806951 | 0.70 | NOS1 (0.48) | KDM4EDYRK1BNOS1DYRK1AALDH1A1 | |
| SCHEMBL22941856 | 0.69 | DYRK1A (0.36) | DYRK1AALDH1A1HSP90AA1IDO1CDK2 | |
| SCHEMBL3726365 | 0.69 | DYRK1A (0.36) | KDM4ENOS1DYRK1AALDH1A1HSP90AA1 | |
| SCHEMBL14629350 | 0.69 | DYRK1A (0.36) | DYRK1AALDH1A1HSP90AA1IDO1CDK2 | |
| SCHEMBL3120521 | 0.69 | DYRK1A (0.36) | DYRK1AHSP90AA1IDO1CDK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630565-B2 | DNA-dependent protein kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4620959-A1 | CYCLIC COMPOUNDS USED AS MULTI-TARGET KINASE INHIBITORS AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2025-09-24 | — | — | EP | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| CN-115768764-B | Parallel ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240182487-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240182481-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630565-B2 | DNA-dependent protein kinase inhibitor | DCK, CHEK1, POLK | KDM4E 859/4885TYRO3 1993/4885DYRK1B 277/4885 |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | KDM4E 4269/4885TYRO3 1635/4885DYRK1B 2895/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | KDM4E 1140/4885TYRO3 55/4885DYRK1B 3444/4885 |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | KDM4E 2622/4885TYRO3 1099/4885DYRK1B 268/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDM4E 2795/4885TYRO3 970/4885DYRK1B 309/4885 |
| US-20240182487-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | KDM4E 3077/4885TYRO3 3214/4885DYRK1B 4371/4885 |
| US-20240182481-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | DPYD, TYMS, TYMP | KDM4E 3769/4885TYRO3 2217/4885DYRK1B 1275/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | KDM4E 2102/4885TYRO3 2606/4885DYRK1B 4766/4885 |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | KDM4E 3909/4885TYRO3 4802/4885DYRK1B 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.